The risk factors influencing between the early and late recurrence in systemic recurrent breast cancer

Journal of Breast Cancer

Volumn 15, Issue 2, 2012, Pages 218-223

  Song, Won Jong ^a   Kim, Kwan Il ^a   Park, Sang Hyun ^a   Kwon, Mi Seon ^a   Lee, Tae Hoon ^a   Park, Heung Kyu ^a   An, Jung Suk ^a  

^a Gachon University   (South Korea)

Author keywords

Breast neoplasms; Recurrence; Risk factors

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIMODALITY CANCER THERAPY; RECURRENCE RISK; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE;

EID: 84865127525     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.2.218     Document Type: Article

References (29)

1. Ministry for Health, Welfare and Family Affairs. Annual Report of Cancer Incidence (2007), Cancer Prevalence (2007), and Survival (1993-2007) in Korea. Seoul: Ministry for Health, Welfare and Family Affairs; 2009. p.14-20.
2. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22.
3. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol 1997;24(4 Suppl 13):S13-9-S13-26.
4. Son BH, Ahn SH, Kwak BS, Kim JK, Kim HJ, Hong SJ, et al. The recurrence rate, risk factors and recurrence patterns after surgery in 3,700 patients with operable breast cancer. J Breast Cancer 2006;9:134-44.
5. Bland KI, Copeland EM III. Breast. In: Schwartz SI, Shires GT, Spencer FC, editors. Principles of Surgery. 6th ed. New York: McGraw-Hill; 1994. p.554-7.
6. Baum M, Badwe RA. Does surgery influence the natural history of breast cancer? In: Wise L, Johnson H Jr, editors. Breast Cancer: Controversies in Management. Armonk: Futura Pub.; 1994. p.61-9.
7. Lyman GH, Kuderer NM, Lyman SL, Debus M, Minton S, Balducci L, et al. Survival following early versus late recurrence of breast cancer. 1997 American Society of Clinical Oncology (ASCO) Annual Meeting. 1997. Abstract #633.
8. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer 1988;62:2226-33.
9. Debonis D, Terz JJ, Eldar S, Hill LR. Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980. J Surg Oncol 1991;48: 158-63.
10. Pater JL, Mores D, Loeb M. Survival after recurrence of breast cancer. Can Med Assoc J 1981;124:1591-5.
11. Min YK, Kim NR, Cho SJ, Kim A, Bae JW, Koo BH. The clinical significance and prognosis of Korean young age (younger or 35 year old) onset breast cancer. J Korean Breast Cancer Soc 2001;4:74-9.
12. Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001;65:217-24.
13. Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, et al. Prognostic markers in node-negative breast cancer: a prospective study. Cytometry B Clin Cytom 2004;59:24-31.
14. Younes M, Laucirica R. Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma. Clin Cancer Res 1997;3:601-4.
15. Noh DY, Han SH, Lee ES, Lee SJ. The prognostic factors and the predictive factors. In: Korean Breast Cancer Society. The Breast. Seoul: Ilchokak; 1999. p.388-412.
16. Park SH, Kim SI, Park BW, Lee KS. Prognostic factors in axillary lymph node negative breast cancer. J Korean Breast Cancer Soc 2004;7:111-20.
17. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006;8: R43.
18. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
19. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 2005;11:433-9.
20. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003;12:92-8.
21. Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Bénard J, et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001;95:266-70.
22. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B, et al. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol 2006;206:702-8.
23. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993;24: 469-76.
24. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors: a surrogate marker? Cancer 2003;97:1321-31.
25. Pinto AE, André S, Pereira T, Nóbrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol 2001;54:543-9.
26. Jung SY, Han W, Shin HJ, Lee JE, Hwang KT, Hwang SE, et al. Usefulness of Ki-67 as a prognostic factor in lymph node-negative breast cancer. J Breast Cancer 2006;9:41-6.
27. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
28. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
29. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429-34.